Ftse Mib
37.698,31
-1,38%
DAX
22.328,77
-1,23%
S&P 500
5.572,07
-0,76%
NASDAQ
17.436,10
-0,18%
Bitcoin
81.860,66
-1,19%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Elevation Oncology Inc (ELEV) Elevation Oncology Inc (ELEV) Notizie

ELEV

Elevation Oncology (ELEV)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ELEV
DataOraFonteTitoloSimboloCompagnia
06/03/202523:12Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ELEVElevation Oncology Inc
06/03/202522:52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELEVElevation Oncology Inc
06/03/202522:30PR Newswire (US)Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business AchievementsNASDAQ:ELEVElevation Oncology Inc
25/02/202513:30PR Newswire (US)Elevation Oncology to Participate in Upcoming Investor ConferencesNASDAQ:ELEVElevation Oncology Inc
19/02/202522:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELEVElevation Oncology Inc
14/02/202519:34Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ELEVElevation Oncology Inc
13/01/202513:30PR Newswire (US)Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming MilestonesNASDAQ:ELEVElevation Oncology Inc
12/12/202413:30PR Newswire (US)Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid TumorsNASDAQ:ELEVElevation Oncology Inc
05/12/202413:30PR Newswire (US)Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024NASDAQ:ELEVElevation Oncology Inc
26/11/202413:30PR Newswire (US)Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare ConferenceNASDAQ:ELEVElevation Oncology Inc
15/11/202401:05Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ELEVElevation Oncology Inc
06/11/202413:30PR Newswire (US)Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business AchievementsNASDAQ:ELEVElevation Oncology Inc
06/11/202413:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ELEVElevation Oncology Inc
23/09/202413:30PR Newswire (US)Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2NASDAQ:ELEVElevation Oncology Inc
03/09/202413:30PR Newswire (US)Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:ELEVElevation Oncology Inc
06/08/202413:10PR Newswire (US)Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business AchievementsNASDAQ:ELEVElevation Oncology Inc
06/08/202413:00PR Newswire (US)Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2NASDAQ:ELEVElevation Oncology Inc
27/06/202413:30PR Newswire (US)Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction CancerNASDAQ:ELEVElevation Oncology Inc
10/05/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ELEVElevation Oncology Inc
09/05/202422:39Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ELEVElevation Oncology Inc
07/05/202413:30PR Newswire (US)Elevation Oncology to Present at the Citizens JMP Life Sciences ConferenceNASDAQ:ELEVElevation Oncology Inc
02/05/202413:30PR Newswire (US)Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business AchievementsNASDAQ:ELEVElevation Oncology Inc
08/04/202422:30PR Newswire (US)Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024NASDAQ:ELEVElevation Oncology Inc
06/03/202413:30PR Newswire (US)Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business AchievementsNASDAQ:ELEVElevation Oncology Inc
06/03/202413:00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ELEVElevation Oncology Inc
05/03/202422:50PR Newswire (US)Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:ELEVElevation Oncology Inc
04/03/202422:21Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ELEVElevation Oncology Inc
04/03/202413:30PR Newswire (US)Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of DirectorsNASDAQ:ELEVElevation Oncology Inc
22/02/202413:30PR Newswire (US)Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in JapanNASDAQ:ELEVElevation Oncology Inc
14/02/202422:45Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ELEVElevation Oncology Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ELEV

La tua Cronologia

BIT
ISP
Intesa Sanpaolo
BIT
UCG
Unicredit
BIT
STLAM
Stellantis NV
BIT
LDO
Leonardo
BIT
ENEL
Enel
BIT
ENI
Eni
BIT
RACE
Ferrari NV
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
BPE
Bper Banca
BIT
SPM
Saipem
BIT
STMMI
ST Microelectronics
BIT
PRY
Prysmian
BIT
CPR
Davide Campari
BIT
G
Generali
BIT
NEXI
Nexi S.p.A
BIT
BAMI
Banco BPM
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci